Conferences

December 17, 2024

Learn how previous therapies, including BCMA-directed treatment and stem cell transplants, can affect CAR T cell therapy outcomes in multiple myeloma.

December 16, 2024

Learn about the study presented in ASH 2024 that explored the idea of urine-free clinical trial response assessments in multiple myeloma.

December 10, 2024

Discover the board's selection of best abstracts at the 66th annual ASH conference.

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

December 10, 2024

The AQUILA trial shows Darzalex is effective in high-risk smoldering multiple myeloma, with 63% of patients progression-free at 5 years.

December 07, 2024

Today, several sessions at the American Society of Hematology conference will cover myeloma research updates. Stay tuned!

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in myeloma research.

November 26, 2024

Explore when CAR T-cell therapy is optimal for RRMM, its benefits, and how it compares to standard treatments.

October 09, 2024

Explore new CAR T and bispecific antibody strategies in myeloma care from the IMS 2024 conference, advancing treatment outcomes and patient care.

October 07, 2024

Learn about new IMS 2024 findings on high-risk multiple myeloma, evolving definitions, improved genetic testing, and cutting-edge treatment strategies.